Financhill
Sell
23

BBC Quote, Financials, Valuation and Earnings

Last price:
$24.27
Seasonality move :
-2.33%
Day range:
$22.58 - $23.91
52-week range:
$22.58 - $31.99
Dividend yield:
1.06%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
9.7K
Avg. volume:
3K
1-year change:
-11.9%
Market cap:
--
Revenue:
--
EPS (TTM):
--

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BBC
Virtus LifeSci Biotech Clinical Trials ETF
-- -- -- -- --
CNCR
Range Cancer Therapeutics ETF
-- -- -- -- --
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
-- -- -- -- --
PBE
Invesco Biotechnology & Genome ETF
-- -- -- -- --
THNR
Amplify Weight Loss Drug & Treatment ETF
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BBC
Virtus LifeSci Biotech Clinical Trials ETF
$22.67 -- -- -- $0.24 1.06% --
CNCR
Range Cancer Therapeutics ETF
$11.98 -- -- -- $0.00 0% --
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
$17.89 -- -- -- $0.00 0% --
PBE
Invesco Biotechnology & Genome ETF
$67.88 -- -- -- $0.01 0.05% --
THNR
Amplify Weight Loss Drug & Treatment ETF
$22.64 -- -- -- $0.36 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BBC
Virtus LifeSci Biotech Clinical Trials ETF
-- 1.540 -- --
CNCR
Range Cancer Therapeutics ETF
-- 1.903 -- --
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
-- 1.221 -- --
PBE
Invesco Biotechnology & Genome ETF
-- 1.078 -- --
THNR
Amplify Weight Loss Drug & Treatment ETF
-- 0.000 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BBC
Virtus LifeSci Biotech Clinical Trials ETF
-- -- -- -- -- --
CNCR
Range Cancer Therapeutics ETF
-- -- -- -- -- --
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
-- -- -- -- -- --
PBE
Invesco Biotechnology & Genome ETF
-- -- -- -- -- --
THNR
Amplify Weight Loss Drug & Treatment ETF
-- -- -- -- -- --

Virtus LifeSci Biotech Clinical Trials ETF vs. Competitors

  • Which has Higher Returns BBC or CNCR?

    Range Cancer Therapeutics ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat Range Cancer Therapeutics ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BBC
    Virtus LifeSci Biotech Clinical Trials ETF
    -- -- --
    CNCR
    Range Cancer Therapeutics ETF
    -- -- --
  • What do Analysts Say About BBC or CNCR?

    Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Range Cancer Therapeutics ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than Range Cancer Therapeutics ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than Range Cancer Therapeutics ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBC
    Virtus LifeSci Biotech Clinical Trials ETF
    0 0 0
    CNCR
    Range Cancer Therapeutics ETF
    0 0 0
  • Is BBC or CNCR More Risky?

    Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.042, which suggesting that the stock is 4.196% more volatile than S&P 500. In comparison Range Cancer Therapeutics ETF has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.096%.

  • Which is a Better Dividend Stock BBC or CNCR?

    Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.06%. Range Cancer Therapeutics ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. Range Cancer Therapeutics ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BBC or CNCR?

    Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than Range Cancer Therapeutics ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than Range Cancer Therapeutics ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while Range Cancer Therapeutics ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for Range Cancer Therapeutics ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBC
    Virtus LifeSci Biotech Clinical Trials ETF
    -- -- -- --
    CNCR
    Range Cancer Therapeutics ETF
    -- -- -- --
  • Which has Higher Returns BBC or EKG?

    First Trust Nasdaq Lux Digi Health Solutions ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat First Trust Nasdaq Lux Digi Health Solutions ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BBC
    Virtus LifeSci Biotech Clinical Trials ETF
    -- -- --
    EKG
    First Trust Nasdaq Lux Digi Health Solutions ETF
    -- -- --
  • What do Analysts Say About BBC or EKG?

    Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Lux Digi Health Solutions ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than First Trust Nasdaq Lux Digi Health Solutions ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than First Trust Nasdaq Lux Digi Health Solutions ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBC
    Virtus LifeSci Biotech Clinical Trials ETF
    0 0 0
    EKG
    First Trust Nasdaq Lux Digi Health Solutions ETF
    0 0 0
  • Is BBC or EKG More Risky?

    Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.042, which suggesting that the stock is 4.196% more volatile than S&P 500. In comparison First Trust Nasdaq Lux Digi Health Solutions ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BBC or EKG?

    Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.06%. First Trust Nasdaq Lux Digi Health Solutions ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. First Trust Nasdaq Lux Digi Health Solutions ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BBC or EKG?

    Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Lux Digi Health Solutions ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than First Trust Nasdaq Lux Digi Health Solutions ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while First Trust Nasdaq Lux Digi Health Solutions ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for First Trust Nasdaq Lux Digi Health Solutions ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBC
    Virtus LifeSci Biotech Clinical Trials ETF
    -- -- -- --
    EKG
    First Trust Nasdaq Lux Digi Health Solutions ETF
    -- -- -- --
  • Which has Higher Returns BBC or PBE?

    Invesco Biotechnology & Genome ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BBC
    Virtus LifeSci Biotech Clinical Trials ETF
    -- -- --
    PBE
    Invesco Biotechnology & Genome ETF
    -- -- --
  • What do Analysts Say About BBC or PBE?

    Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than Invesco Biotechnology & Genome ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBC
    Virtus LifeSci Biotech Clinical Trials ETF
    0 0 0
    PBE
    Invesco Biotechnology & Genome ETF
    0 0 0
  • Is BBC or PBE More Risky?

    Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.042, which suggesting that the stock is 4.196% more volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.828, suggesting its less volatile than the S&P 500 by 17.198%.

  • Which is a Better Dividend Stock BBC or PBE?

    Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.06%. Invesco Biotechnology & Genome ETF offers a yield of 0.05% to investors and pays a quarterly dividend of $0.01 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BBC or PBE?

    Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBC
    Virtus LifeSci Biotech Clinical Trials ETF
    -- -- -- --
    PBE
    Invesco Biotechnology & Genome ETF
    -- -- -- --
  • Which has Higher Returns BBC or THNR?

    Amplify Weight Loss Drug & Treatment ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat Amplify Weight Loss Drug & Treatment ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BBC
    Virtus LifeSci Biotech Clinical Trials ETF
    -- -- --
    THNR
    Amplify Weight Loss Drug & Treatment ETF
    -- -- --
  • What do Analysts Say About BBC or THNR?

    Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Amplify Weight Loss Drug & Treatment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than Amplify Weight Loss Drug & Treatment ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than Amplify Weight Loss Drug & Treatment ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBC
    Virtus LifeSci Biotech Clinical Trials ETF
    0 0 0
    THNR
    Amplify Weight Loss Drug & Treatment ETF
    0 0 0
  • Is BBC or THNR More Risky?

    Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.042, which suggesting that the stock is 4.196% more volatile than S&P 500. In comparison Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BBC or THNR?

    Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.06%. Amplify Weight Loss Drug & Treatment ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.36 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. Amplify Weight Loss Drug & Treatment ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BBC or THNR?

    Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than Amplify Weight Loss Drug & Treatment ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than Amplify Weight Loss Drug & Treatment ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while Amplify Weight Loss Drug & Treatment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for Amplify Weight Loss Drug & Treatment ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBC
    Virtus LifeSci Biotech Clinical Trials ETF
    -- -- -- --
    THNR
    Amplify Weight Loss Drug & Treatment ETF
    -- -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is American Tower Stock Undervalued?
Is American Tower Stock Undervalued?

The market action of late has been nothing short of…

Is Broadcom Stock Overvalued?
Is Broadcom Stock Overvalued?

The semiconductor company Broadcom Inc. (NASDAQ:AVGO) is having a stellar…

4 Top Dividend Stocks to Buy Now
4 Top Dividend Stocks to Buy Now

If you’re looking for steady income, dividend stocks are a…

Stock Ideas

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 39x

Sell
47
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 114x

Sell
39
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 36x

Alerts

Buy
87
CEG alert for Jan 11

Constellation Energy [CEG] is up 25.15% over the past day.

Sell
1
MCY alert for Jan 11

Mercury General [MCY] is down 19.87% over the past day.

Buy
84
ATZAF alert for Jan 11

Aritzia [ATZAF] is up 17.63% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock